Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532787 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL18355748 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL3835193 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL20156432 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL28746286 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL9160736 | 0.73 | MEN1 (0.48) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL14487061 | 0.73 | HRH4 (0.57) | HRH4HRH3 | |
| SCHEMBL3626130 | 0.71 | — | — | |
| SCHEMBL13440656 | 0.70 | BRD4 (0.55) | SMN1; SMN2MEN1KMT2AKDM4EGAA | |
| SCHEMBL7272830 | 0.70 | GAA (0.52) | SMN1; SMN2MEN1KMT2AKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458823-B1 | 4,5-DIAMINO DERIVATIVES OF (1H)- PYRAZOLES AND THEIR USE IN THE TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION, WHICH INCLUDE, URINARY INCONTINENCE, HYPERTENSION, ASTHAMA, PREMATURE LABOR, IRRITABLE BOWL SYNDROM | WYETH | 2002-10-01 | — | — | US | disclosed |
| US-20020032198-A1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-6319941-B1 | TREATMENT OF SMOOTH MUSCLE SPASTICITY OR EXCESS MUSCLE CONTRACTION SUCH AS URGE URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-20 | — | — | US | disclosed |
| US-6313149-B1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-06 | — | — | US | disclosed |
| US-6172222-B1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2001-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032198-A1 | Diaminopyrazoles | ODC1, AOC1, CLIC1 | SMN1; SMN2 63/4885MEN1 2864/4885KMT2A 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.